{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:01:13Z","timestamp":1769068873283,"version":"3.49.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"HepatitisWA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"DOI":"10.1186\/s12875-025-02865-3","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:26:19Z","timestamp":1747121179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers"],"prefix":"10.1186","volume":"26","author":[{"given":"Jonathan","family":"Hallett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corie","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshana","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roanna","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2865_CR1","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis. Geneva: World Health Organization. 2016. No. WHO\/HIV\/2016.06."},{"key":"2865_CR2","unstructured":"Burnet Institute, Kirby Institute. Australia\u2019s progress towards hepatitis C elimination: Annual report 2020. Melbourne, Australia 2020."},{"key":"2865_CR3","volume-title":"Viral hepatitis mapping project: National report 2018\u201319. Darlinghurst","author":"J MacLachlan","year":"2020","unstructured":"MacLachlan J, Smith C, Towell V, Cowie B. Viral hepatitis mapping project: National report 2018\u201319. Darlinghurst. NSW, Australia: Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). 2020."},{"issue":"6","key":"2865_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/jvh.12852","volume":"25","author":"B Hajarizadeh","year":"2018","unstructured":"Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepatitis. 2018;25(6):640\u20138.","journal-title":"J Viral Hepatitis"},{"key":"2865_CR5","unstructured":"Department of Health. Western Australian hepatitis C strategy 2019\u20132023. Perth, Australia. 2019."},{"issue":"3","key":"2865_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11901-024-00655-6","volume":"23","author":"M Abdallah","year":"2024","unstructured":"Abdallah M, Waked I, El-Kassas M. Global hepatitis C virus Elimination\u2014Where are we?? Curr Hepatol Rep. 2024;23(3):373\u20137.","journal-title":"Curr Hepatol Rep"},{"issue":"5","key":"2865_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/joim.12972","volume":"286","author":"JV Lazarus","year":"2019","unstructured":"Lazarus JV, Peric\u00e0s JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med. 2019;286(5):503\u201325.","journal-title":"J Intern Med"},{"key":"2865_CR8","doi-asserted-by":"crossref","unstructured":"Goodyear T, Ti L, Carrieri P, Small W, Knight R. Everybody living with a chronic disease is entitled to be cured: challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy. 2020;81.","DOI":"10.1016\/j.drugpo.2020.102766"},{"key":"2865_CR9","volume-title":"HIV, viral hepatitis and sexually transmissible infections in Australia annual surveillance report 2024: hepatitis C","author":"J King","year":"2024","unstructured":"King J, Kwon J, McManus H, Gray R, McGregor. S. HIV, viral hepatitis and sexually transmissible infections in Australia annual surveillance report 2024: hepatitis C. Sydney, Australia: The Kirby Institute, UNSW. 2024."},{"key":"2865_CR10","unstructured":"Burnet Institute and Kirby Institute. Australia\u2019s progress towards hepatitis C elimination: annual report 2024. Melbourne; 2024."},{"key":"2865_CR11","doi-asserted-by":"crossref","unstructured":"Heard E, Smirnov A, Massi L, Selvey L. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: experiences of patients who inject drugs accessing treatment in general practice settings in Australia. J Subst Abuse Treat. 2021;127.","DOI":"10.1016\/j.jsat.2021.108460"},{"issue":"1","key":"2865_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","volume":"16","author":"JI Tsui","year":"2021","unstructured":"Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, et al. Treat my whole person, not just my condition\u2019: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract. 2021;16(1):52.","journal-title":"Addict Sci Clin Pract"},{"issue":"5","key":"2865_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1071\/AH19194","volume":"44","author":"A Rashidi","year":"2020","unstructured":"Rashidi A, Higgs P, Carruthers S. Factors affecting hepatitis C treatment intentions among aboriginal people in Western Australia: a mixed-methods study. Aust Health Rev. 2020;44(5):755\u201362.","journal-title":"Aust Health Rev"},{"issue":"2","key":"2865_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.idh.2018.10.006","volume":"24","author":"C Wright","year":"2019","unstructured":"Wright C, Cogger S, Hsieh K, Goutzamanis S, Hellard M, Higgs P. I\u2019m obviously not dying so it\u2019s not something I need to sort out today: considering hepatitis C treatment in the era of direct acting antivirals. Infect Disease Health. 2019;24(2):58\u201366.","journal-title":"Infect Disease Health"},{"key":"2865_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. Hep C\u2019s like the common Cold\u2019: Understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354.","journal-title":"Drug Alcohol Depend"},{"key":"2865_CR16","doi-asserted-by":"publisher","first-page":"103387","DOI":"10.1016\/j.drugpo.2021.103387","volume":"96","author":"J Gunn","year":"2021","unstructured":"Gunn J, McNally S, Ryan J, Layton C, Bryant M, Walker S, et al. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene. Int J Drug Policy. 2021;96:103387.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"2865_CR17","doi-asserted-by":"publisher","first-page":"e0207226","DOI":"10.1371\/journal.pone.0207226","volume":"13","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS ONE. 2018;13(11):e0207226.","journal-title":"PLoS ONE"},{"key":"2865_CR18","doi-asserted-by":"crossref","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouche B, Klein M. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. Int J Drug Policy. 2021;96.","DOI":"10.1016\/j.drugpo.2021.103247"},{"issue":"2","key":"2865_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3138\/canlivj.2019-0002","volume":"3","author":"MJ Biondi","year":"2020","unstructured":"Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. Can Liver J. 2020;3(2):165\u201376.","journal-title":"Can Liver J"},{"issue":"5","key":"2865_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/M17-0118","volume":"167","author":"S Kattakuzhy","year":"2017","unstructured":"Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, et al. Expansion of treatment for hepatitis C virus infection by task shifting to Community-Based nonspecialist providers. Ann Intern Med. 2017;167(5):311\u20138.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2865_CR21","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","volume":"9","author":"E Oru","year":"2021","unstructured":"Oru E, Trickey A, Shirali R, Kanters S, Easterbrook P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Global Health. 2021;9(4):e431\u201345.","journal-title":"Lancet Global Health"},{"issue":"1","key":"2865_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-019-4635-7","volume":"19","author":"A Radley","year":"2019","unstructured":"Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res. 2019;19(1):1\u201313.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"2865_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.13949","volume":"39","author":"E Day","year":"2019","unstructured":"Day E, Hellard M, Treloar C, Bruneau J, Martin NK, \u00d8vrehus A, et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int. 2019;39(1):20\u201330.","journal-title":"Liver Int"},{"key":"2865_CR24","doi-asserted-by":"crossref","unstructured":"Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. editors. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Seminars in liver disease. Thieme Medical. 2018.","DOI":"10.1055\/s-0038-1666841"},{"issue":"4","key":"2865_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/SGA.0000000000000458","volume":"43","author":"JA Richmond","year":"2020","unstructured":"Richmond JA, Gallagher L, McDonald L, O\u2019Sullivan M, Fitzsimmons C, Pedrana A. Achieving hepatitis C elimination by using Person-Centered, Nurse-Led models of care: A discussion of four international case studies. Gastroenterol Nurs. 2020;43(4):303\u20139.","journal-title":"Gastroenterol Nurs"},{"issue":"3","key":"2865_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1071\/SH19101","volume":"17","author":"N Iranpour","year":"2020","unstructured":"Iranpour N, Dore GJ, Martinello M, Matthews GV, Grebely J, Hajarizadeh B. Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. Sex Health. 2020;17(3):223\u201330.","journal-title":"Sex Health"},{"issue":"8","key":"2865_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5694\/mja2.50544","volume":"212","author":"N Scott","year":"2020","unstructured":"Scott N, Sacks-Davis R, Wade AJ, Stoove M, Pedrana A, Doyle JS, et al. Australia needs to increase testing to achieve hepatitis C elimination. Med J Aust. 2020;212(8):365\u201370.","journal-title":"Med J Aust"},{"issue":"7","key":"2865_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5694\/mja2.51204","volume":"215","author":"F Stafford","year":"2021","unstructured":"Stafford F, Dore GJ, Clackett S, Martinello M, Matthews GV, Grebely J, et al. Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. Med J Australia. 2021;215(7):332\u20133.","journal-title":"Med J Australia"},{"issue":"7","key":"2865_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/jgh3.12593","volume":"5","author":"D Busingye","year":"2021","unstructured":"Busingye D, Chidwick K, Simpson V, Dartnell J, Dore J, Balcomb G. The changing characteristics of patients with chronic hepatitis C prescribed direct acting antiviral medicines in general practice since listing of the medicines on the Australian pharmaceutical benefits scheme. JGH Open. 2021;5(7):813\u20139.","journal-title":"JGH Open"},{"issue":"1","key":"2865_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"issue":"7","key":"2865_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"9","key":"2865_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/imj.14648","volume":"50","author":"E Heard","year":"2020","unstructured":"Heard E, Massi L, Smirnov A, Selvey LA. Prescribing direct-acting antivirals to treat hepatitis C virus in a general practice setting in Australia: \u2018so why not do it\u2019? Intern Med J. 2020;50(9):1053\u20138.","journal-title":"Intern Med J"},{"issue":"1","key":"2865_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12072-018-9902-x","volume":"13","author":"S Johnson","year":"2019","unstructured":"Johnson S, Aluzaite K, Taar A, Schultz M. Identifying barriers to treatment of HCV in the primary care setting. Hep Intl. 2019;13(1):58\u201365.","journal-title":"Hep Intl"},{"key":"2865_CR34","doi-asserted-by":"publisher","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","volume":"206","author":"A Marshall","year":"2020","unstructured":"Marshall A, Grebely J, Dore G, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists\u2014The practitioner experience. Drug Alcohol Depend. 2020;206:107705.","journal-title":"Drug Alcohol Depend"},{"key":"2865_CR35","doi-asserted-by":"crossref","unstructured":"Ortiz-Paredes D, Amoako A, Lessard D, Engler K, Lebouch\u00e9 B, Klein MB. Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: patients and treatment provider perceptions. Can Liver J. 2021;5(2):e20210020.","DOI":"10.3138\/canlivj-2021-0020"},{"issue":"5","key":"2865_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/jvh.13259","volume":"27","author":"D Pourmarzi","year":"2020","unstructured":"Pourmarzi D, Smirnov A, Hall L, Thompson H, FitzGerald G, Rahman T. Enablers and barriers for the provision of community-based HCV treatment: a case study of a real\u2010world practice. J Viral Hepatitis. 2020;27(5):484\u201396.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"2865_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2055-6640(20)30254-5","volume":"4","author":"JA Richmond","year":"2018","unstructured":"Richmond JA, Wallace J. Implementation of hepatitis C cure in Australia: one year on. J Virus Eradication. 2018;4(2):115\u20137.","journal-title":"J Virus Eradication"},{"issue":"1","key":"2865_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imj.13662","volume":"48","author":"R Sud","year":"2018","unstructured":"Sud R, Tiwari N, Forner P, Dowdell L, Freiman J, Zekry A. General practitioners require more support to prescribe direct acting antiviral therapy for hepatitis C. Intern Med J. 2018;48(1):105\u20136.","journal-title":"Intern Med J"},{"issue":"1","key":"2865_CR39","first-page":"E201","volume":"9","author":"Z von Aesch","year":"2021","unstructured":"von Aesch Z, Craig-Neil A, Shah H, Antoniou T, Meaney C, Pinto AD. Family medicine\u2013directed hepatitis C care and barriers to treatment: a mixed-methods study. Can Med Association Open Access J. 2021;9(1):E201\u20137.","journal-title":"Can Med Association Open Access J"},{"key":"2865_CR40","unstructured":"Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, et al. A survey of hepatitis C management by Victorian gps after PBS-listing of direct-acting antiviral therapy. Royal Australian College of General Practitioners 2017;235\u201340."},{"issue":"3","key":"2865_CR41","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/jvh.13443","volume":"28","author":"D Whiteley","year":"2021","unstructured":"Whiteley D, Speakman E, Elliott L, Davidson K, Hamilton E, Jarvis H, et al. Provider-related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis. J Viral Hepatitis. 2021;28(3):528\u201337.","journal-title":"J Viral Hepatitis"},{"key":"2865_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-017-0644-y","volume":"6","author":"WM Bramer","year":"2017","unstructured":"Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Reviews. 2017;6:1\u201312.","journal-title":"Syst Reviews"},{"key":"2865_CR43","volume-title":"EndNote 20","author":"Clarivate Analytics","year":"2020","unstructured":"Clarivate Analytics. EndNote 20. Philadelphia, PA: Clarivate Analytics. 2020."},{"issue":"1","key":"2865_CR44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Reviews. 2016;5(1):210.","journal-title":"Syst Reviews"},{"key":"2865_CR45","volume-title":"Qualtrics. Utah","author":"Qualtrics","year":"2024","unstructured":"Qualtrics. Qualtrics. Utah. USA: Qualtrics. 2024."},{"issue":"2","key":"2865_CR46","first-page":"106","volume":"120","author":"R Koepke","year":"2021","unstructured":"Koepke R, Akhtar WZ, Kung VM, Seal DW, Salisbury-Afshar E, Westergaard RP. Hepatitis C treatment knowledge and practice among family medicine physicians in Wisconsin during the current hepatitis C epidemic. WMJ. 2021;120(2):106\u201313.","journal-title":"WMJ"},{"issue":"5","key":"2865_CR47","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/cid\/civ384","volume":"61","author":"CA Chastain","year":"2015","unstructured":"Chastain CA, Beekmann SE, Wallender EK, Hulgan T, Stapleton JT, Polgreen PM. Hepatitis C management and the infectious diseases physician: a survey of current and anticipated practice patterns. Clin Infect Dis. 2015;61(5):792\u20134.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2865_CR48","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12875-024-02507-0","volume":"25","author":"P Cox-North","year":"2024","unstructured":"Cox-North P, Wiggins L, Stockton J, Huriaux E, Fliss M, Evaskus L, et al. Provider reported implementation barriers to hepatitis C elimination in Washington state. BMC Prim Care. 2024;25(1):252.","journal-title":"BMC Prim Care"},{"issue":"4","key":"2865_CR49","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10900-020-00794-z","volume":"45","author":"RK Doshi","year":"2020","unstructured":"Doshi RK, Ruben M, Drezner K, Lachmann A, Kuo I, Chanes-Mora P, et al. Knowledge, attitudes, and behaviors related to hepatitis C screening and treatment among health care providers in Washington, DC. J Community Health. 2020;45(4):785\u201394.","journal-title":"J Community Health"},{"issue":"3","key":"2865_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1037\/rmh0000200","volume":"46","author":"DM Evon","year":"2022","unstructured":"Evon DM, Hurt CB, Carpenter DM, Rhea SK, Hennessy CM, Zule WA. Substance use disorder treatment providers\u2019 knowledge and opinions toward testing and treatment of chronic hepatitis C in rural North Carolina. J Rural Mental Health. 2022;46(3):162.","journal-title":"J Rural Mental Health"},{"key":"2865_CR51","doi-asserted-by":"crossref","unstructured":"Falade-Nwulia O, McAdams-Mahmoud A, Irvin R, Niculescu A, Page K, Mix M et al. Primary care providers knowledge, attitude and practices related to hepatitis C screening and treatment in the oral direct acting antiviral agents era. J Community Med Health Educ. 2016;6(5).","DOI":"10.4172\/2161-0711.1000481"},{"key":"2865_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.drugpo.2018.10.012","volume":"63","author":"J Grebely","year":"2019","unstructured":"Grebely J, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, et al. Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: the C-SCOPE study. Int J Drug Policy. 2019;63:29\u201338.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"2865_CR53","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jvh.13119","volume":"26","author":"A Litwin","year":"2019","unstructured":"Litwin A, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study. J Viral Hepatitis. 2019;26(9):1094\u2013104.","journal-title":"J Viral Hepatitis"},{"key":"2865_CR54","doi-asserted-by":"publisher","first-page":"102138","DOI":"10.1016\/j.pmedr.2023.102138","volume":"32","author":"H Park","year":"2023","unstructured":"Park H, Brown C, Wilson DL, Huang PL, Hern\u00e1ndez-Con P, Horne P, et al. Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the united States. Prev Med Rep. 2023;32:102138.","journal-title":"Prev Med Rep"},{"issue":"11","key":"2865_CR55","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1080\/09540121.2019.1587353","volume":"31","author":"M Shumway","year":"2019","unstructured":"Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED. Direct-acting antiviral treatment for HIV\/HCV patients in safety net settings: patient and provider preferences. AIDS Care. 2019;31(11):1340\u20137.","journal-title":"AIDS Care"},{"key":"2865_CR56","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1007\/s10620-016-4097-2","volume":"61","author":"M Thomson","year":"2016","unstructured":"Thomson M, Konerman MA, Choxi H, Lok AS. Primary care physician perspectives on hepatitis C management in the era of direct-acting antiviral therapy. Dig Dis Sci. 2016;61:3460\u20138.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2865_CR57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3138\/canlivj-2021-0032","volume":"5","author":"S Sirpal","year":"2022","unstructured":"Sirpal S, Chandok N. Barriers to hepatitis C diagnosis and treatment in the DAA era: preliminary results of a community-based survey of primary care practitioners. Can Liver J. 2022;5(1):96\u2013100.","journal-title":"Can Liver J"},{"issue":"1","key":"2865_CR58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12954-024-01057-z","volume":"21","author":"E Bredenberg","year":"2024","unstructured":"Bredenberg E, Callister C, Dafoe A, Holliman BD, Rowan SE, Calcaterra SL. Subspecialty physicians\u2019 perspectives on barriers and facilitators of hepatitis C treatment: a qualitative study. Harm Reduct J. 2024;21(1):140.","journal-title":"Harm Reduct J"},{"issue":"1","key":"2865_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s43058-023-00484-6","volume":"4","author":"A Desai","year":"2023","unstructured":"Desai A, O\u2019Neal L, Reinis K, Brown C, Stefanowicz M, Kuang A, et al. Identifying barriers and facilitators along the hepatitis C care cascade to inform human-centered design of contextualized treatment protocols for vulnerable populations in Austin, Texas: a qualitative study. Implement Sci Commun. 2023;4(1):98.","journal-title":"Implement Sci Commun"},{"key":"2865_CR60","doi-asserted-by":"crossref","unstructured":"Gonzalez CJ, Kapadia SN, Niederdeppe J, Dharia A, Talal AH, Lloyd AR et al. The state of hepatitis C elimination from the front lines: A qualitative study of Provider-Perceived gaps to treatment initiation. J Gen Intern Med. 2024;15(7):1\u20139.","DOI":"10.1007\/s11606-024-08807-6"},{"key":"2865_CR61","doi-asserted-by":"crossref","unstructured":"Javanbakht M, Archer R, Klausner J. Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the united States? Perspectives from hepatitis C treatment providers in a large urban healthcare system. PLoS ONE. 2020;15(11).","DOI":"10.1371\/journal.pone.0241615"},{"key":"2865_CR62","doi-asserted-by":"publisher","first-page":"102964","DOI":"10.1016\/j.drugpo.2020.102964","volume":"86","author":"AD Marshall","year":"2020","unstructured":"Marshall AD, Hopwood M, Grebely J, Treloar C. Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: identified challenges for widespread implementation. Int J Drug Policy. 2020;86:102964.","journal-title":"Int J Drug Policy"},{"key":"2865_CR63","doi-asserted-by":"crossref","unstructured":"Scarborough J, Aylward P, Miller ER. General practitioners\u2019 perceptions of the provision of direct-acting antivirals for hepatitis C within Australian private general practice: an exploratory qualitative study. Aust J Prim Health. 2023;29(6):661\u2013669.","DOI":"10.1071\/PY22271"},{"issue":"5","key":"2865_CR64","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/15248399231169928","volume":"24","author":"E DiDomizio","year":"2023","unstructured":"DiDomizio E, Chandra DK, Nichols L, Villanueva M, Altice FL. Challenges to achieving HCV micro-elimination in people with HIV in the united States: provider perspectives and the role of implicit bias. Health Promot Pract. 2023;24(5):998\u20131008.","journal-title":"Health Promot Pract"},{"issue":"9","key":"2865_CR65","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/jvh.12910","volume":"25","author":"AJ Wade","year":"2018","unstructured":"Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, et al. Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C. J Viral Hepatitis. 2018;25(9):1089\u201398.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"2865_CR66","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12939-021-01420-7","volume":"20","author":"T Goodyear","year":"2021","unstructured":"Goodyear T, Brown H, Browne AJ, Hoong P, Ti L. I want to get better, but\u2026 identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Int J Equity Health. 2021;20(1):81.","journal-title":"Int J Equity Health"},{"issue":"4","key":"2865_CR67","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3138\/canlivj.2018-0012","volume":"1","author":"J Chan","year":"2018","unstructured":"Chan J, Young J, Cox J, Nitulescu R, Klein MB. Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: a National survey of Canadian infectious diseases physicians. Can Liver J. 2018;1(4):231\u20139.","journal-title":"Can Liver J"},{"issue":"2","key":"2865_CR68","first-page":"313","volume":"32","author":"SN Facente","year":"2018","unstructured":"Facente SN, Burk K, Eagen K, Mara ES, Smith AA, Lynch CS. New treatments have changed the game: hepatitis C treatment in primary care. Infect Disease Clin. 2018;32(2):313\u201322.","journal-title":"Infect Disease Clin"},{"issue":"10","key":"2865_CR69","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/1359105315626786","volume":"22","author":"VA Sublette","year":"2017","unstructured":"Sublette VA, Smith SK, George J, McCaffery K, Douglas MW. Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals\u2019 perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. J Health Psychol. 2017;22(10):1300\u201311.","journal-title":"J Health Psychol"},{"issue":"11","key":"2865_CR70","doi-asserted-by":"publisher","first-page":"e0142770","DOI":"10.1371\/journal.pone.0142770","volume":"10","author":"AJ Wade","year":"2015","unstructured":"Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, et al. The cascade of care for an Australian Community-Based hepatitis C treatment service. PLoS ONE. 2015;10(11):e0142770.","journal-title":"PLoS ONE"},{"issue":"1","key":"2865_CR71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-023-00780-3","volume":"20","author":"MRA Hassan","year":"2023","unstructured":"Hassan MRA, Chan H-K, Nordin M, Yahya R, Sulaiman WRW, Merican SAA, et al. Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs. Harm Reduct J. 2023;20(1):48.","journal-title":"Harm Reduct J"},{"key":"2865_CR72","doi-asserted-by":"publisher","first-page":"104785","DOI":"10.1016\/j.drugpo.2025.104785","volume":"139","author":"S Griffin","year":"2025","unstructured":"Griffin S, Walker S, Holmes JA, Reid B, Callus A, Belzer M, et al. Quick, simple, and friendly: Understanding the acceptability and accessibility of a nurse and peer-led, mobile model of hepatitis C care adjacent to community corrections in Australia. Int J Drug Policy. 2025;139:104785.","journal-title":"Int J Drug Policy"},{"issue":"Supplement3","key":"2865_CR73","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1093\/infdis\/jiad198","volume":"229","author":"S Handanagic","year":"2024","unstructured":"Handanagic S, Shadaker S, Drobeniuc J, Tsereteli M, Alkhazashvili M, Adesigbin C, et al. Lessons learned from global hepatitis C elimination programs. J Infect Dis. 2024;229(Supplement3):S334\u201341.","journal-title":"J Infect Dis"},{"issue":"6","key":"2865_CR74","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5694\/mja2.51885","volume":"218","author":"MB MacIsaac","year":"2023","unstructured":"MacIsaac MB, Whitton B, Hubble A, Cogger S, Penn M, Weeks A, et al. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility. Med J Aust. 2023;218(6):256\u201361.","journal-title":"Med J Aust"},{"issue":"1","key":"2865_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13063-024-08212-8","volume":"25","author":"P Fathima","year":"2024","unstructured":"Fathima P, Jones M, D\u2019Souza R, Totterdell J, Andric N, Abbott P, et al. Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The methodical evaluation and optimisation of targeted incentives for accessing treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study. Trials. 2024;25(1):387.","journal-title":"Trials"},{"key":"2865_CR76","volume-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement (June 2020)","author":"C Hepatitis","year":"2020","unstructured":"Hepatitis C, Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (June 2020). Melbourne, Australia.: Gastroenterological Society of Australia.. 2020."},{"issue":"5","key":"2865_CR77","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","volume":"7","author":"EB Cunningham","year":"2022","unstructured":"Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, et al. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(5):426\u201345.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2865_CR78","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/cid\/ciz546","volume":"70","author":"AJ Wade","year":"2020","unstructured":"Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, et al. Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs. Clin Infect Dis. 2020;70(9):1900\u20136.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2865_CR79","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/13814788.2021.1954616","volume":"27","author":"SL Leong","year":"2021","unstructured":"Leong SL, Teoh SL, Fun WH, Lee SWH. Task shifting in primary care to tackle healthcare worker shortages: an umbrella review. Eur J Gen Pract. 2021;27(1):198\u2013210.","journal-title":"Eur J Gen Pract"},{"key":"2865_CR80","doi-asserted-by":"publisher","first-page":"102633","DOI":"10.1016\/j.drugpo.2019.102633","volume":"76","author":"AY Palmer","year":"2020","unstructured":"Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, et al. A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. Int J Drug Policy. 2020;76:102633.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"2865_CR81","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/jvh.13927","volume":"31","author":"MS Sulkowski","year":"2024","unstructured":"Sulkowski MS, Martinez A, Tyson GL, Scholz K, Franco RA, Kohli A, et al. Leveraging opportunities for treatment\/user simplicity (LOTUS): navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs. J Viral Hepatitis. 2024;31(6):342\u201356.","journal-title":"J Viral Hepatitis"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-02865-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-02865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:03:53Z","timestamp":1747166633000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-025-02865-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2865"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-02865-3","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval to conduct this study was granted by the Curtin University Human Research Ethics Committee (HRE2021-0632) in accordance with the Declaration of Helsinki and the National Health and Medical Research Council\u2019s National Statement on Ethical Conduct in Human Research. The research was undertaken with the informed consent of participants. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}